Stevenage Bioscience Catalyst
Gunnels Wood Road
About ReViralReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.
The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion which will enter clinical trials in H2/2016.
Founder and CSO: Stuart Cockerill
COO: Rachel Harland
CFO: Max Herrmann
Please click here for clinical trial information.
14 articles with ReViral
ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, Green Sands E
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection
ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus, announced that the U.S. Food and Drug Administration has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.
ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced the appointment of Alan A. Musso to the position of Chief Financial Officer, effective October 21, 2019
ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019.
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)
Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research
ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme
Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
3/1/2019Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.
ReViral announced the successful completion of a US$55 million Series B financing.
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, Or...
The study of RV521, an oral RSV fusion inhibitor, achieved all its primary and secondary endpoints (significantly reduced viral load, reduced total mucus weight and reduced clinical symptoms) compared to placebo.
ReViral Announces Good Safety And Pharmacokinetics From Phase I Programme For RSV Antiviral RV521 In Healthy Volunteers
ReViral Initiates Phase 1 Clinical Trial Of Potent Oral Inhibitor Against Respiratory Syncytial Virus